LNCAROD and cancer: Treatment of the rats with doses of NVP which corresponded to those which were hepatocarcinogenic (Klimisch et al 1997a) did not lead to significant changes of AROD activities preferentially mediated by CYP1A, 2B and 3A, respectively, in the cancer target organ, the rat liver.